WhiteLab Genomics
Uses its AI platform, ALFRED, to design the parts of genomic medicines (AAV and non-viral delivery vehicles and synthetic promoters), then tests them in animals, aiming to own and license the validated designs.
Money and evidence
Latest round, Series B, 2026-10-06: the record then held 1 research entry, highest level 4. The first research entry is dated 2026-05-13; the highest level so far is 4 (Tested in the physical world).
Rounds and research, on one timeline
- 2026-10-06Series BRound
$26M
For: in vivo validation of its AI-designed viral and non-viral delivery and programmable payloads, and commercial expansion in North America, Europe and Asia
Wet labCommercial roll-out
The company states $26M; European outlets give EUR 23.2M. AVP's François Robinet and Yaday Health's Daniel Teper join the board.
Lead · AVPYaday HealthBlast ClubExisting investor · Omnes CapitalExisting investor · Debiopharm Innovation Fund
On the deal: Daniel Teper (Managing Partner, Yaday Health, joins the board); François Robinet (Managing Partner, AVP, joins the board)
By this date the record held 1 research entry, highest level 4
Announced by the company · whitelabgx.com ↗On the timeline →
- 2026-05-13Research
Level 4 · Tested in the physical world
WhiteLab Genomics says AAV carriers designed by its AI platform put about 50 times more DNA into the brain than AAV9 after one injection into a vein in mice, with none found in the liver
Many gene therapies for brain disease are injected into the brain or the spinal fluid because the blood-brain barrier stops medicines carried in the blood, and AAV9 given by vein also reaches organs such as the liver, which the company says creates potential safety and dosing limits. A designed shell that gets into the brain from a vein, and not into the liver, would change how such therapies are given, and it was designed from receptor biology rather than found by screening.
- 2022-09-13Series ARound
$10M
For: growing the R&D team and US operations, and developing its data sets and algorithms for payloads and vectors
HiringModels and platformData generation
Debiopharm's release says it co-leads, alongside Omnes Capital; WhiteLab's CEO calls it the company's first institutional round.
Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.